Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus LIPO HEPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus LIPO HEPIN.
ANGIOMAX vs LIPO-HEPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
LIPO-HEPIN (unfractionated heparin) binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Initial IV bolus 80 units/kg, then continuous IV infusion 18 units/kg/hr; or subcutaneous 5000 units every 8-12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
1-2 hours (therapeutic doses); dose-dependent: 30-60 min at low doses, up to 4-6 hours at high doses. Heparin is eliminated by a saturable zero-order process, leading to nonlinear pharmacokinetics. Clinical context: prolonged half-life in renal impairment or hepatic disease.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Renal: 30-60% as unchanged drug; minor biliary/fecal (<10%). Clearance predominantly via hepatic metabolism (desulfation) and reticuloendothelial system uptake.
Category C
Category C
Anticoagulant
Anticoagulant